Home

News & Infos
The Biosimilars Association Austria warns of end of biosimilars price regulation at the end of the year
The 4 years of biosimilars price regulation in Austria have proven successful. Since April 2017, 22 biosimilars have been included in the reimbursement code, saving approximately EUR 247 million (2017-2019)....
[Read more here]
Our new CSR Report
Astro Pharma presents the new CSR Report 2020.
[Read more here]
Annual meeting of the Austrian Society for Reproductive Medicine and the in-vitro fertilisation Society
From 8. until 10. of October 2020 the annual meeting of the Austrian Society for Reproductive Medicine and the in-vitro fertilisation Society took place in Mauerbauch, close to Vienna. Astro...
[Read more here]
Increasing the value of Biosimilars
The austrian scientific magazine „Österreichische Apothekerzeitung” published an article about „Increasing the value of Biosimilars”. This document outlines the benefits of Biosimilars in enabling affordable treatment and widening patient access...
[Read more here]
A new patient information material for a better awareness of Biosimilars
On the 22nd of September 2020 Dr. Sabine Möritz-Kaisergruber introduced a new patient information material concerning Biosimilars at a press conference. [Press release (in german)] [patient information material (in 8...
[Read more here]
imh Conference 2020 on Biosimilars 29.-30.09.2020
On 29. – 30. 9. 2020, the imh would like to invite you to the pharmaceutical forum based on the biosimilar topics: market penetration / regulations / reimbursement. Specialists from...
[Read more here]
Potential for savings through the usage of biosimillars
New Austrian Study of Biosimilars Association Austria proves: Around EUR 357 million savings through biosimilars in the last 12 years
[Read more here]
Information for patients on Biosimilars 2016
This edition of information for patients on biosimilars was prepared jointly by representatives of the European Medicines Agency (EMA), the European Commission and corresponding third parties.
[Read more here]
Products
Our international network
Our international network
Products
Astropharma Products
Our Company
Astropharma our Company
Astro Pharma
Astro Pharma is a family-run business from Austria and consists of 30 pharmaceutical professionals who know the Austrian market like no other. We specialise in innovative and economical drugs and niche products which are indispensable for the health system of the future and can take the strain off it permanently. We offer our own products such as antibiotics and vaccines and are general agents in Austria for international drug companies. An international network combined with unique local knowledge prepare us for any challenge: With our outstanding service and product range, we start where others reach their limits
Astro Pharma – We introduce ourselves!

Biosimilarsverband
Sales of biosimilars
Astro Pharma is a founding member of the Austrian Biosimilar Association (BiVÖ). Astro Pharma and other members of the Association, A-med GmbH, ratiopharm Arzneimittel Vertriebs GmbH, Sandoz GmbH and STADA Arzneimittel GmbH, account for more than 85% of the Austrian biosimilar market. The president of the voluntary lobby group of biosimilar providers and producers is Sabine Möritz-Kaisergruber, Managing Partner of Astro Pharma. The Austrian Biosimilar Association was founded in 2016 and is committed to providing the best care for Austrian patients with top-quality biopharmaceutical drugs at affordable prices. Biosimilars are biological drugs which can significantly take the strain off the healthcare system because of their consistent quality, safety and effectiveness. For more information about the Austrian Biosimilar Association, please visit: www.biosimilarsverband.at More information: www.biosimilarsverband.at
biosimilarsverband